ProfoundBio Announces Further Advancement of Lead Programs – PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic

PRO1160 first patient dosed in the US China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023 /PRNewswire/ — ProfoundBio, a clinical-stage…

Click here to view original post